...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Myconostica Announces Appointment of David Evans as Non-Executive Director

| Print |
Thursday, 07 October 2010 11:00 (UTC + 2)

myconostica_logo_

Manchester, United Kingdom, October 7, 2010 / b3c newswire / - Myconostica Ltd, the medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the immediate appointment of Mr David Evans as independent Non-Executive Director.

 

Myconostica, which is based in the UK but has an international network of distributors, has a number of molecular diagnostic products already on the market, and is developing a portfolio of additional tests with the aim of providing healthcare professionals with a complete diagnostic toolkit for life-threatening fungal infections.

 

As the former CFO of Shield Diagnostics Ltd, David guided the business through its IPO and then, as its CEO, through its merger with Axis Biochemical ASA to form Axis-Shield plc, a Fully Listed diagnostics company. He is currently Chairman or Non-Executive Director of a number of companies within the diagnostic and life science space including Epistem Holdings plc, Immunodiagnostic Systems Holdings plc and Omega Diagnostics Group plc, all AIM listed diagnostic companies. David was Chairman of Manchester-based personalised medicine/ companion diagnostic business DxS Ltd for three years until June 2009 and during this time he steered DxS’s transformation from a reference genetics laboratory to a thriving molecular diagnostics products company.

 

Jerel Whittingham, Myconostica’s Executive Chairman, said “I am delighted to welcome Mr Evans to the Board of Myconostica. His experience and track record in building value for investors within the diagnostic sector is remarkable. We believe it is a strong endorsement of Myconostica’s business and prospects that we have been able to attract such a high quality executive. My board colleagues and I look forward to working with him.”

 

David Evans, said “I am delighted to be joining the Board of Myconostica at a point in time where I believe it is at its inflection point and the trajectory from here is significantly upward.”

 

 

About Myconostica Ltd. - www.myconostica.co.uk
Myconostica Ltd, a UK-based medical diagnostic company specialises in rapid and highly specific tests for life-threatening fungal infections. Traditional methods of the detection of fungal infections are well documented as being relatively insensitive and slow. Tests provided by Myconostica aim to allow healthcare professionals to rapidly identify patients infected thus enabling clinicians to prescribe appropriate drug therapy. Myconostica is developing and commercialising a portfolio of real-time molecular diagnostic tests for life-threatening fungal infections. Over 10 million people are at risk of these infections each year in Europe and North America alone.

 

 

For further information please contact:

 

Myconostica Ltd
Spencer Kerry
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
+44 (0)161 998 7239